Home > Healthcare > Pharmaceuticals > Vaccines > Meningococcal Vaccines Market

Meningococcal Vaccines Market Share

Report ID: GMI6586
Published Date: Aug 2023
Report Format: PDF

Download Free Sample

Meningococcal Vaccines Market Share

The prominent players in the global meningococcal vaccines market are

Sanofi SA
GlaxoSmithKline plc
Pfizer Inc.
Novartis AG
Nuron Biotech
Hualan Biological Engineering Inc
Serum Institute of India Ltd.
JN International Merck & Co., Inc
Walwax Biotechnology Co.

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for meningococcal vaccines was valued at USD 4.3 billion in 2023 and is expected to reach USD 7.8 billion by 2032, primarily driven by the rising prevalence of meningitis worldwide.

The conjugate vaccines segment held a major market share of 51.1% in 2022 as these vaccines offer advantages in terms of efficacy, and the breadth of protection they provide against multiple serogroups of Neisseria meningitidis.

In 2022, North American market for meningococcal vaccines held a revenue share of 57% and is anticipated to show considerable growth through 2032, driven by favourable initiatives and aids from governments as well as significant research & development expenditures in the region.

Sanofi SA, GlaxoSmithKline plc, Pfizer Inc., Novartis AG, Nuron Biotech, Hualan Biological Engineering Inc, Serum Institute of India Ltd., JN International Merck & Co., Inc, Walwax Biotechnology Co., and others.